Sotorasib (also known as LUMAKRAS) is an innovative targeted therapy for KRASG12C-mutant non-small cell lung cancer (NSCLC). Due to its unique pharmacological mechanism of action, it has demonstrated excellent efficacy in clinical treatment. Currently, this drug is not available in China and is not included in the national medical insurance catalog; patients must obtain it through overseas purchases.
Sotorasib Purchase Channels
1. Purchase Channels
For patients who need to purchase this drug, choosing a suitable and reliable purchase channel is crucial to initiating treatment. Since there is currently no domestic market access, legitimate overseas channels are the primary choice. These include internationally renowned chain pharmacies, channels partnered with legitimate medical institutions, and compliant overseas online drug purchase platforms. When choosing these channels, the key is to confirm that they have legal drug sales qualifications and possess a good industry reputation and user feedback to avoid purchasing counterfeit or substandard drugs.
2. Precautions
Before purchasing medication, be sure to communicate fully with your attending physician to clarify the indications, dosage, and precautions, and confirm that the medication meets your individual treatment needs. When choosing overseas channels, verify the legality of the channel through official certification and qualification checks, and request relevant qualification certificates if necessary. Pay attention to storage conditions during drug transportation to avoid affecting efficacy due to improper transportation. Do not easily trust low-priced channels of unknown origin to avoid drug quality risks or legal issues.
Friendly Reminder: Sotorasib is a prescription drug. Please use it under the advice and supervision of your doctor. Inform your doctor promptly of any problems encountered during medication use, and do not change the dosage or method of administration without authorization.
